In addition, in 2013, Ashabi et al. indicated that the inhibition of ERK1/2 activation, p38 MAPK activation, or both attenuates neuroinflammation in an Aβ-induced AD model [51]. This evidence concerns the gene MAPK3 and Alzheimer disease.